Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AtriCure (ATRC) Shares Outstanding (Diluted Average) (2019 - 2025)

Historic Shares Outstanding (Diluted Average) for AtriCure (ATRC) over the last 7 years, with Q3 2025 value amounting to $47.9 million.

  • AtriCure's Shares Outstanding (Diluted Average) rose 173.02% to $47.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.9 million, marking a year-over-year increase of 173.02%. This contributed to the annual value of $47.0 million for FY2024, which is 141.66% up from last year.
  • AtriCure's Shares Outstanding (Diluted Average) amounted to $47.9 million in Q3 2025, which was up 173.02% from $47.7 million recorded in Q2 2025.
  • AtriCure's 5-year Shares Outstanding (Diluted Average) high stood at $47.9 million for Q3 2025, and its period low was $44.6 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $46.3 million, with a median of $46.3 million in 2023.
  • Its Shares Outstanding (Diluted Average) has fluctuated over the past 5 years, first soared by 929.14% in 2021, then crashed by 64.94% in 2022.
  • Quarter analysis of 5 years shows AtriCure's Shares Outstanding (Diluted Average) stood at $46.0 million in 2021, then decreased by 0.65% to $45.7 million in 2022, then rose by 1.24% to $46.3 million in 2023, then grew by 1.42% to $47.0 million in 2024, then grew by 2.03% to $47.9 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $47.9 million in Q3 2025, compared to $47.7 million in Q2 2025 and $47.4 million in Q1 2025.